Board of Directors

Drew Fromkin has more than 28 years of leadership experience in major areas of the healthcare industry, including the biopharmaceuticals, life sciences and healthcare services sectors. He has an accomplished track record leading public and private companies through all stages of growth, including product development and commercial operations. Prior becoming the CEO of Tarveda Therapeutics, Mr. Fromkin served as President, CEO and Director of Clinical Data, Inc. (NASDAQ: CLDA) where he transformed the Company from a traditional diagnostics business with a sub-$100 million market capitalization to an innovative biopharmaceutical and personalized medicine company. Clinical Data was acquired for $1.2 billion by Forest Laboratories. Prior to Clinical Data, Mr. Fromkin served as President and CEO of DoctorQuality, Inc. (acquired by Quantros, Inc.), President, CEO and Director of Endo Surgical Devices, Inc. and Corporate Vice President, Business Development, for Merck-Medco, a wholly-owned subsidiary of Merck & Co. Mr. Fromkin began his career at Health Information Technologies, Inc. as General Manager of their subsidiary, MCA, and Director of Marketing and Payer Alliances for the parent company. He also recently served as a director and Chair of the compensation committee for Tobira Therapeutics, Inc. (TBRA), which has recently been acquired for $1.7 billion by Allergan (AGN). Mr. Fromkin was named to Business Week's "CEOs 40 and Under" list while at Clinical Data. Mr. Fromkin holds a B.A. from Brandeis University.

Dennis A. Ausiello, MD, is the Jackson Professor of Clinical Medicine at Harvard Medical School and the Physician-in-Chief, Emeritus of the Department of Medicine at Massachusetts General Hospital. Previously, Dr. Ausiello served as Physician-in-Chief of the Department of Medicine at MGH from 1996-2013, and as the Chief of the Renal Unit at MGH from 1983-1996. He is a renowned cell biologist and has made a substantial contribution to knowledge of epithelial biology in the areas of membrane protein trafficking, ion channel regulation and signal transduction. Dr. Ausiello has published over 150 papers, chapters and textbooks and serves as the co-editor of Cecil's Textbook of Medicine (Elsevier), now in its 23rd edition. A nationally recognized leader in academic medicine, Dr. Ausiello was elected to the Institute of Medicine of the National Academy of Sciences in 1999 and the American Academy of Arts and Sciences in 2003.

Dr. Barrett is a General Partner at New Enterprise Associates (NEA). He specializes in biotechnology and works with members of NEA's healthcare investment group on medical devices, healthcare information systems, and healthcare services companies. He is a director of Cardioxyl Pharmaceuticals, GlycoMimetics, Inhibitex, Nucleonics, Peptimmune, Predictive Biosciences, Proteostasis Therapeutics, Ruxton Pharmaceuticals, Sensors for Medicine and Science, Supernus Pharmaceuticals, Targacept, and Zosano Pharma. Prior to joining NEA, Dr. Barrett served as Founder, Chairman, and CEO of Sensors for Medicine and Science, where he remains Chairman. Prior to that, he led three NEA-funded companies, serving as Chairman and CEO of Genetic Therapy, President and CEO of Life Technologies, and President and CEO of Bethesda Research Labs. Previously, he worked in various divisions of GlaxoSmithKline. Dr. Barrett received a Ph.D. in Biochemistry at the University of Tennessee, an M.B.A. from the University of Santa Clara, and a B.S. in Chemistry from Boston College.

Dr. Farokhzad is a physician-scientist-entrepreneur and has authored approximately 115 papers and holds more than 140 issued/pending US and International patents. The technologies that Dr. Farokhzad and colleagues have developed formed the basis for the launch of three biotechnology companies: BIND Therapeutics (NASDAQ: BIND), Selecta Biosciences, Tarveda Therapeutics. He served as Director on the Board of Directors of BIND (2006 - 2014), and currently serves as Vice Chairman on the Board of Directors of Selecta. Dr. Farokhzad was elected to the College of the Fellows of the American Institute of Medical and biological Engineering. He was a recipient of the 2013 RUSNANOPRIZE, one of the largest international nanotechnology prizes, for the development and industrialization of nanoparticle technologies for medical applications. In 2014, he received the Golden Door Award from the International Institute of New England, and in the same year he was also selected by Thomson Reuters as one of the World’s Most Influential Scientific Minds. In 2013, the Boston Globe selected him among the top innovators in Massachusetts and the Boston Business Journal selected him among the Health Care Champions for his Innovations. In 2012, he was among the regional Ernst & Young Entrepreneur of the Year awardees. Dr. Farokhzad completed his post-graduate clinical and post-doctoral research trainings, respectively, at the BWH/HMS and MIT in the laboratory of Dr. Robert Langer. He received his M.D. and M.A. from Boston University School of Medicine.

Nilesh joined Novo Ventures (US) Inc. in Boston in 2015. Prior to joining Novo, Nilesh was Senior Director at MS Ventures where he invested in early stage life science companies. Nilesh led the initial investments and served on the Boards of Auxogyn, Canbex, f-Star, Padlock Therapeutics, RaNA Therapeutics, Raze Therapeutics and TocopheRx. In addition to his venture role, Nilesh has successfully led several strategic licensing transactions at Merck Serono in oncology and autoimmune therapeutic areas.

Nilesh received his PhD from the Department of Chemistry and Chemical Biology at Harvard University. He holds an MBA from Harvard University, and did his undergraduate degree in Natural Sciences from the University of Cambridge, UK.

Dr. Langer is renowned for his pioneering contributions in the use of biomaterials in drug delivery and tissue engineering. He is the author of more than 1,175 scientific papers and a named inventor on more than 800 issued or pending patents worldwide; his patents have been licensed or sublicensed to more than 220 pharmaceutical, chemical, biotechnology, and medical device companies. Dr. Langer is the recipient of more than 210 major awards, including the National Medal of Science, the highest civilian honor bestowed by the United States; the Charles Stark Draper Prize, considered the equivalent of the Nobel Prize in the field of engineering; the Millennium Prize, the world’s largest technology prize; the Priestley Medal, the highest award conferred by the American Chemical Society; and the Lemelson-MIT prize, the world’s largest prize for invention. He is the most cited engineer in history and is one of few individuals to have been elected to all three U.S. national academies—the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine. He is the co-founder of more than 20 companies, including BIND Biosciences, Selecta Biosciences, Momenta, and Transform. Dr. Langer holds a B.S. from Cornell University and an Sc.D. from MIT, both in Chemical Engineering.

Dr. Guido Magni is a Partner with Versant Ventures. Guido previously served as a Managing Director of EuroVentures, a Versant incubator, where he was intimately involved in several biotech investments including Synosia (sold to Biotie Therapies), Flexion and Okairos.

Guido was previously the Global Head of the Medical Science Department of Roche Pharmaceuticals in Basel, Switzerland. During his twelve-year term at Roche, Guido oversaw the development and the registration of a large number of new chemical and biological entities including Cellcept, Pegasys, Mabthera, Xeloda, Herceptin, Tamiflu and Tarceva.

Currently, Guido serves on the Board of Biotie and AM Pharma, with previous board positions at Adolor Corporation and Anabasis Pharma before their recent acquisitions.

Guido was trained at the University of Padua with a specialization in neuro-psychiatry. He is the co-author of over 100 peer-reviewed papers.

Michael A. Metzger is President and Chief Operating Officer since May 2015. Prior to joining Syndax, Mr. Metzger was President and COO from December 2013 to October 2014 and President and Chief Executive Officer and a member of the board of directors of Regado Biosciences, Inc., a former publicly traded company that merged with Tobira Therapeutics, Inc., from October 2014 to May 2015, where he oversaw the company’s successful merger with Tobira Therapeutics, Inc. in 2015. Previously, Mr. Metzger served as Executive Vice President and Chief Operating Officer at Mersana Therapeutics, Inc., a privately held biopharmaceutical company developing novel immunoconjugate therapies for cancer, from March 2011 to November 2013, and in senior business development positions including leading mergers and acquisitions at Forest Laboratories, LLC, which was acquired by Allergan plc, a publicly traded company, from 2006 to February 2011. Prior to Forest, Mr. Metzger served as Vice President Corporate Development at Onconova Therapeutics, Inc., from 2001 until 2006, and was a Managing Director at MESA Partners, Inc., a venture capital firm, from 1997 to 2001. Mr. Metzger received a B.A. from George Washington University and an M.B.A. in Finance from the New York University Stern School of Business.

Aymeric Sallin is the Founder and CEO of NanoDimension, a nanotechnology-focused venture capital firm, with offices in Zurich, Switzerland and Menlo Park, California. Mr. Sallin is currently on the Board of Directors of Crocus Technology SA and Selecta Biosciences as well as the Advisory Board of the Physics Department of the Federal Institute of Technology (EPFL) in Lausanne, Switzerland. Since 2001, he has actively promoted and stimulated nanotechnology around the world, receiving the "NSTI Fellow Award" for outstanding contributions to the advancement of the international nanotechnology community. In 2010, he was voted “Top 20 Under 40” in Switzerland by Bilan magazine and as one of Switzerland’s 300 most influential people in 2011. Mr. Sallin holds a Masters in Physical Engineering from EPFL.

Frank Torti joined NEA in 2007 and focuses on investments in biopharmaceuticals, medical devices, and healthcare services. He has been actively involved in the firm’s private and public investments in healthcare, including  Alimera Sciences, Cadence Pharmaceuticals (acquired by Mallinckrodt plc), CITIC Pharmaceuticals (acquired by Shanghai Pharmaceuticals), Dermira, Galera Therapeutics, Neotract, Novast Pharmaceuticals, Peplin (acquired by LEO Pharma), Rigel, Solta Medical (acquired by Valeant), and Tarveda Therapeutics. Prior to joining NEA, Dr. Torti worked for the Duke University Center for Clinical & Genetic Economics, where he was involved in clinical trials research and economic evaluations of multinational clinical trials. Dr. Torti’s experience also includes public market investing at the Wasatch Advisors mutual fund family and business development work with the consumer-directed healthcare startup Revolution Health Group. Dr. Torti received his medical degree from the University of North Carolina School of Medicine, his MBA with distinction from Harvard Business School, and his BA with highest honors from the University of North Carolina, where he was a Morehead Scholar.